Navigation Links
InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
Date:11/6/2008

- Third quarter net loss narrows on higher revenue due to Roche milestone -

BRISBANE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the third quarter and nine months ended September 30, 2008. InterMune reported a net loss for the third quarter of 2008 of $12.5 million, or $0.32 per share, compared with a net loss of $23.1 million, or $0.66 per share, in the third quarter of 2007.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "Third quarter and recent events have highlighted our significant progress on pirfenidone and ITMN-191. On October 16, Shionogi's Japanese NDA for pirfenidone was approved, making pirfenidone the first drug approved for idiopathic pulmonary fibrosis (IPF) in any major market in the world. We reported exceptional patient retention in our Phase 3 CAPACITY program for pirfenidone in IPF and we set the expectation for announcement of top-line results from CAPACITY in January or February of 2009. With ITMN-191, we remain committed to announcing top-line results of our triple combination study of ITMN-191 with Pegasys(R) (pegylated interferon alfa-2a) and Copegus(R) (ribavirin) during this quarter."

Results for Third Quarter 2008

InterMune reported total revenue in the third quarter of 2008 of $23.3 million, compared with total revenue of $11.4 million in the third quarter of 2007. Total revenue in the third quarter of 2008 primarily consisted of revenue from the collaboration with Roche for the development of protease inhibitors, including ITMN-191 (R7227), which totaled $15.8 million in the third quarter of 2008, compared with $0.8 million in the same quarter of 2007. Third quarter 2008 collaborati
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)...  NuGene International, Inc. ("NuGene") (OTCQB: NUGN), announced ... has added another internationally recognized researcher to its ... internationally recognized researcher in bio-inspired materials and bio-materials ... University, China , Professor Guan ... North Carolina, Chapel Hill. Following a postdoctoral training ...
(Date:3/30/2015)... March 30, 2015    Intrexon Corporation ... biology, and Merck Serono, the biopharmaceutical business of ... today announced an exclusive strategic collaboration and license ... T-cell (CAR-T) cancer therapies. This collaboration advances Merck ... that modulate the immune system,s natural ability to ...
(Date:3/30/2015)... LONDON , March 30, 2015 ... Patienten auf    Richmond Pharmacology ist das ... Nationalen Amyloidose-Zentrum am Royal Free Hospital in ... Phase-3-Studie zur Untersuchung eines RNAi-Therapeutikums Studienversuche an einem ... Behandlung von Transthyretin vermittelter Amyloidose entwickelt (ATTR), einer ...
(Date:3/29/2015)... 2015 As a symbol of its ... our pharmaceutical manufacturing clients, Whitehouse Laboratories is excited to ... Berkenstock Race Team for the 2015 race season. Success ... but a strong sense of precision and attention to ... success in the quality control testing laboratory. Sponsorship of ...
Breaking Biology Technology:UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2
... Andrew Ryan Varian Australia Pty. Ltd., Mulgrave, 3170, Victoria, ... , The role of major, minor ... area of scientific research. In particular, research on the value of trace ... , The advent of atomic absorption ...
... Inc. , Introduction ... veterinary drugs. The use of these in food production is already ... the European Union because of a possible increased cancer-risk through long-term ... nitrofurans contamination has been found in warm-water prawns, shrimp, and chicken. ...
... in the yeast Saccharomyces cerevisiae : Detection in vivo using ... Paul Gavin# and Mark Prescott # , Ph.D , ... # Department of Biochemistry and Molecular Biology, Monash University, , ... * Technical assistance: Varian Australia Pty Ltd, Mulgrave, Victoria 3170, , ...
Cached Biology Technology:Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 2Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 3Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 4Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 5Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 6Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 7Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 8Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 9Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 10Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 11Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 12Analysis of Nitrofurans Metabolites by Positive Ion Electrospray LC/MS/MS 2Cytosolic expression of Green Fluorescent Protein (GFP) and its derivatives , in the yeast Saccharomyces cerevisiae: Detection in vivo using , the Varian Cary Eclipse 2Cytosolic expression of Green Fluorescent Protein (GFP) and its derivatives , in the yeast Saccharomyces cerevisiae: Detection in vivo using , the Varian Cary Eclipse 3Cytosolic expression of Green Fluorescent Protein (GFP) and its derivatives , in the yeast Saccharomyces cerevisiae: Detection in vivo using , the Varian Cary Eclipse 4Cytosolic expression of Green Fluorescent Protein (GFP) and its derivatives , in the yeast Saccharomyces cerevisiae: Detection in vivo using , the Varian Cary Eclipse 5
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... advertising campaign on CNBC television starting March 30 th ... commence airing in New York markets. ... said: "We are excited about our new ad campaign following ...
(Date:3/19/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... aired this week on Washington DC,s ... a segment "The Next Great Thing", host Laura Evans ... pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/16/2015)... Between 16 and 20 ... innovations in biometric identification at the CeBIT exhibition ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) , ... at the forefront: the company,s all new BiometricGate ... Germany . BiometricGate is the first ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... are on the verge of unleashing the power of the ... as decades of research begins to bear fruit. Boron has ... but is now attracting fast growing research interest and investment ... to tackle cancer and infectious diseases, potentially overcoming limitations and ...
... emissions is not the only threat to the planet. Changes ... widespread use of fertilizers, are also damaging both water quality ... Brush, from Johns Hopkins University in Baltimore, USA, in her ... large estuary on the Atlantic coast of the USA. Her ...
... has consisted in the development of class antagonismsthe exploitation ... Karl Marx and Frederick Engels, The Communist Manifesto ... group well being, it also may increase the potential ... control: which individuals gain the spoils and which toil ...
Cached Biology News:European researchers harness unique properties of boron to develop new drugs and diagnostics 2European researchers harness unique properties of boron to develop new drugs and diagnostics 3Fertilizers -- a growing threat to sea life 2Caste in the colony 2
Rab1A...
... LYZL6 ( Abpromise for all ... Synthetic peptide: DWLCL AFVE SKFNISKINE ... to amino acids 46-100 of Human ... ID: 57151 ...
Request Info...
Mouse monoclonal [DJR3] to DcR1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Biology Products: